Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users
New brand boosts protein, iron, calcium content
Up against new Daily Harvest, Herbalife products
By Jessica DiNapoli
NEW YORK, May 21(Reuters) -Nestle NESN.S will market a new, $5 line of frozen pizzas and protein-enriched pastas in the United States which it says it designed specifically for people taking drugs such as Wegovy or Ozempic for weight loss.
The world's biggest food company, which sells DiGiorno pizza and Stouffer's meals to major grocers, said it developed the new products with more protein, iron and calcium for people taking the wildly popular appetite-suppressing drugs, called GLP-1 agonists.
Tom Moe, president of Nestle USA's meal division, said it will pitch the meals in a new brand, Vital Pursuit, as "food solutions" for people who want to complement their use of the drugs with "the right nutrition - high protein, good fiber, the right minerals," like potassium and vitamin C.
The products, set to hit supermarket shelves in October, are priced at $4.99 and under, a little more expensive than a DiGiorno four cheese personal pan pizza, which is sold at Target for $4.79.
Nestle, whose biggest brands include KitKat chocolate bars and Nescafe coffee, started working on companion products to the GLP-1 drugs last year.
"We moved real fast on this," Moe said.
Nestle CEO Mark Schneider said in October the company was “carefully” monitoring whether spreading use of the drugs might dent demand for its food products. He also said at the time that Nestle was working on “companion products” that might serve to limit the "loss of lean muscle mass” in people on the drugs.
Some investors have been worried that food companies will lose sales due to the hunger-suppressing drugs. But executives at companies like Nestle and Conagra CAG.N see the medications presenting a new opportunity to pitch products such as beef jerky, popcorn and frozen meals. Mondelez MDLZ.O executives have said their snack bars fit perfectly into the diet of a GLP-1 patient.
Roughly one in eight U.S. adults have taken the GLP-1 drugs, but Goldman Sachs estimates that 10 million to 70 million U.S. consumers could be taking them in the next four years.
Moe said Nestle spoke with people on the drugs to develop the meals and will be offering them samples soon. The Swiss-based company first introduced the brand to Walmart WMT.N, and then other big retailers such as Kroger KR.N and Target TGT.N, he said.
RACE ON TO FILL PROTEIN GAP
People on GLP-1 medications are at risk of losing lean muscle mass as they shed pounds and often don’t feel like eating very much, said Ethan Lazarus, an obesity doctor in Colorado. Some who take the drugs develop aversions to protein and fat, said Lazarus, who is a speaker for GLP-1-drugmakers Eli Lilly LLY.N and Novo Nordisk NOVOb.CO.
“There’s definitely a need to make sure people get adequate protein,” said Lazarus, who once served on the advisory board for Nestle Health Sciences, which makes Optifast, a weight loss product.
“If food companies are going to try to pivot to make simple-flavored foods that are rich in protein and easy on the stomach, they might be popular ... I’m not sure how it’s different from (previous generations of packaged) diet food.”
Nestle already makes weight loss shakes and supplements that cater to people on the drugs, who can experience side effects like nausea and constipation.
Nutrition company Herbalife HLF.N earlier this year began selling some of its most popular shake mixes and fiber supplements in bundles targeting people on the drugs.
Herbalife is looking at expanding the bundles to other markets, including South America and in particular Brazil, where GLP-1 drugs are growing in popularity, said Luigi Gratton, chairman of the company's nutrition advisory board.
Meal kit provider Daily Harvest is also offering a GLP-1 companion food collection, a box of meals that includes a broccoli and white bean soup and bean and cabbage bowl for $118.46.
Sales have been "relatively slow," said Daily Harvest CEO Ricky Silver. The company isn't aggressively pushing into selling its kits to people on the medications, he said.
"We definitely see it as an opportunity (but) not something we need to drastically pivot our focus toward," Silver said. "Our food is already foundationally good for people taking these drugs."
Nestle's Vital Pursuit's portions will range from approximately eight to 10 ounces (227 to 284 grams), Moe said.
In the 1980s, Nestle introduced diet brand Lean Cuisine, with meals focused on calorie control, while Vital Pursuit offers more fiber, protein and other "macronutrients," Moe said.
Reporting by Jessica DiNapoli in New York; Editing by Sonali Paul
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
